Takeda Oral Tyk2 Inhibitor, Acquired in Nimbus Deal, Raises the Bar on Psoriasis

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

From Computational Discovery to a New Psoriasis Drug: Jeb Keiper on The Long Run
Mentoring Young Scientists: Jay Bradner and Andy Plump on The Long Run
Fighting COVID-19 & Racism: Andy Plump on The Long Run
The Oxygen-Providing, High-Autonomy M&A Model: A Sign of Things to Come